Intervention not reported
Daptomycin and cefazolin versus cefazolin (vascular surgery) · surgical patients
It is very uncertain whether the intervention changes daptomycin and cefazolin versus cefazolin (vascular surgery) (very low certainty).
1 finding from 1 review
Intervention not reported
Daptomycin versus vancomycin or semisynthetic penicillin · patients with MRSA‐infected non surgical wounds
It is very uncertain whether the intervention changes daptomycin versus vancomycin or semisynthetic penicillin (very low certainty).
1 finding from 1 review
Intervention not reported
Ertapenem versus piperacillin/tazobactam · patients with MRSA‐infected non surgical wounds
It is very uncertain whether the intervention changes ertapenem versus piperacillin/tazobactam (very low certainty).
1 finding from 1 review
Intervention not reported
Moxifloxacin versus piperacillin/tazobactam followed by amoxycillin/clavulanate · patients with MRSA‐infected non surgical wounds
It is very uncertain whether the intervention changes moxifloxacin versus piperacillin/tazobactam followed by… (very low certainty).
1 finding from 1 review
All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Febrile patients and episodes · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Bacteraemia · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Re‐infection · children with lower urinary tract infection
It is very uncertain whether the intervention changes re‐infection (very low certainty).
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Recurrence · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day cefadroxil changes persistent bacteriuria compared with 10‐day ampicillin (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day cefadroxil changes persistent symptoms compared with 10‐day ampicillin (very low certainty).
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether single‐dose fosfomycin changes persistent bacteriuria compared with single‐dose netilmicin (very low certainty).
1 finding from 1 review
Recurrence · children with lower urinary tract infection
It is very uncertain whether single‐dose fosfomycin changes recurrence compared with single‐dose netilmicin (very low certainty).
1 finding from 1 review
Intervention not reported
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether the intervention changes persistent bacteriuria (very low certainty).
1 finding from 1 review
Intervention not reported
Recurrence · children with lower urinary tract infection
It is very uncertain whether the intervention changes recurrence (very low certainty).
1 finding from 1 review
total treatment failure · patients with human Brucellosis
Doxycycline+Rifampicin probably leads to higher total treatment failure compared with doxycycline+Streptomycin (moderate certainty).
1 finding from 1 review
Minor adverse drug reactions · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in minor adverse drug reactions compared with doxycycline+Streptomycin (low certainty).
1 finding from 1 review
total treatment failure · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in total treatment failure compared with quinolones+Rifampicin (moderate certainty).
1 finding from 1 review